Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Brief description of study
This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer or vincristine for lymphoma. Participants will be enrolled over approximately 1-year.The purpose of this present study is to prospectively collect clinical and biomarker data from patients receiving neurotoxic chemotherapy who are at risk for developing CIPN.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer,taxane
-
Age: Between 18 Years - 99 Years
-
Gender: Female
Updated on
09 Mar 2024.
Study ID: 833120
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
